LN-145 vs Olvimulogene nanivacirepvec
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: No discrete molecular target · full Non-Small Cell Lung Cancer pipeline
LN-145
Developed by Iovance Biotherapeutics
NCT03645928 · Phase 2 · terminated
This open-label study gave tumor-infiltrating lymphocyte therapy (lifileucel or LN-145), alone or combined with checkpoint inhibitors, to patients with advanced melanoma, head-and-neck cancer or non-small-cell lung cancer across multiple non-randomized treatment cohorts, with objective response rate as the primary measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2030 · NCT04614103 (registry estimate)
Reported efficacy
Objective Response Rate (Up to 60 months); Safety Profile Measured by Grade ≥3 TEAEs (Up to 60 months); Percentage of patients for whom lifileucel is successfully manufactured and meets release specification (Up to 60 months): Cohort 3B (NSCLC) interim data, objective response rate: 21.4% in the full analysis set (n=28), 25% in the efficacy-evaluable set (n=24); one complete response and five partial responses.
Result source: NCT03645928
Olvimulogene nanivacirepvec
Developed by Genelux Corporation and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT06463665 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | LN-145 | Olvimulogene nanivacirepvec |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- LN-145
- —Not reported
- Olvimulogene nanivacirepvec
- —Not reported
OS, median
- LN-145
- —Not reported
- Olvimulogene nanivacirepvec
- —Not reported
ORR
- LN-145
- —Not reported
- Olvimulogene nanivacirepvec
- —Not reported
Duration of response, median
- LN-145
- —Not reported
- Olvimulogene nanivacirepvec
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Olvimulogene nanivacirepvec: no structured comparison results are available for Non-Small Cell Lung Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
LN-145
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LN-145's landscape · Olvimulogene nanivacirepvec's landscape